Skip to content
Clinic Wiz

Clinic Owner Brief

Pricing, pharmacy rules and the business of running a clinic.

Short, sourced stories for independent clinic owners. We read what regulators, journals and companies have published, put it in plain language, and link every original.

The lead story

Hims & Hers Previews Peptides+, Citing the HHS Draft Peptide Policy

One day after HHS announced a draft peptide compounding policy, Hims & Hers CEO Andrew Dudum previewed a Peptides+ specialty and named BPC-157 and TB-500 as offerings "to follow when allowable." A major national telehealth player is building product plans on a policy that has not been finalized.

November 3, 2026 · 6 min read · Curated industry storyRead the story

The archive

18 sourced stories

Public source events from February through October 2026. Curated from public FDA and Gallup records, with original analysis clearly identified. No private pricing data, health claims or treatment advice.

  1. Industry · November 3, 2026Hims & Hers Previews Peptides+, Citing the HHS Draft Peptide PolicyOne day after the Department of Health and Human Services announced a draft peptide compounding policy, a major national telehealth company previewed a peptide specialty, with its release framed as a response to the announcement. Hims & Hers co-founder and CEO Andrew Dudum previewed a new Peptides+ specialty in an October 29 company release, naming sermorelin, glutathione, B12, NAD+ and L-carnitine as planned offerings, "with BPC-157 and TB-500 to follow when allowable." [1]
  2. Industry · November 2, 2026Weight-Loss Spending at Med Spas Flattened in 2025Patients spent $2.2 billion on weight loss at U.S. medical aesthetics practices in 2025, roughly the same as the year before. It is the first full year without double- or triple-digit growth for the category since GLP-1 drugs arrived in 2021, and it changes the math for any owner deciding whether to add or keep a weight-loss line. [1]
  3. Policy · November 1, 2026ASHP Backs the Guardrails, Not the Shortcut, on Peptide CompoundingOrganized pharmacy's response to the federal peptide compounding policy came within a day of its announcement, and it is not a celebration. ASHP says the policy's guardrails match what it asked for, and that relying on enforcement discretion instead of rulemaking is the wrong way to hold them up. [1]
  4. Policy · October 31, 2026The Peptide Comment Window Is Open, and Narrower Than It LooksThe HHS peptide enforcement policy completed its move onto the formal record on October 30: published in the Federal Register, assigned a docket, and opened for public comment through November 13. Two days after the policy first surfaced, the process question has replaced the policy question: what does this comment window actually decide? [1][3]
  5. Business · October 30, 2026Lilly Takes Seven in Ten Medicare Bridge Patients as GLP-1 Guidance Rises AgainEli Lilly reported third-quarter results on October 29 that beat expectations on nearly every line: revenue of $24.4 billion, up 39%, and full-year guidance raised to $91 to $92 billion. Inside the numbers was a more strategic detail: roughly seven in ten patients using the new Medicare GLP-1 Bridge program are on a Lilly medicine, and most of them are new to this class of drugs entirely. [1][2]
  6. Policy · October 29, 2026HHS Proposes Interim Enforcement Policy for Six Compounded PeptidesA notice filed October 28 in the Federal Register announces a draft HHS policy under which the department says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound six unapproved peptides (BPC-157, epitalon, KPV, MOTS-c, semax and TB-500) while formal rulemaking over the compounding bulk list continues. The policy is a draft published for comment, and it states that it establishes no rights and is not binding. [1][2]
  7. Business · October 28, 2026Walgreens Extends GLP-1 Support Beyond the Prescription PickupWalgreens is adding coverage checks, prior authorization help and follow-up pharmacist calls around GLP-1 medications. The move raises the support bar for every clinic that prescribes them.
  8. Business · September 27, 2026GLP-1 prices are moving. The terms matter more than the headline.What changed
  9. Research · October 5, 2026Retatrutide's Phase 3 Results, Read Carefully: What Is Published, What Is ToplineEli Lilly's retatrutide, an investigational injectable that activates GIP, GLP-1 and glucagon receptors, has now reported results from several Phase 3 trials, and the first full peer-reviewed paper is out. This explainer separates what has been published from what is still sponsor-reported topline, and lays out what the data do and do not show.
  10. Business · September 25, 2026The Price Conversation Is Moving From a Number to a Set of QuestionsWhat is the price of a GLP-1 program? Without knowing what a patient is actually buying, a single number may conceal more than it reveals. An advertised charge might be described as a visit, a membership or a product purchase. The FDA's recent warnings about compounded GLP-1 marketing make another distinction material: what product is offered, whether it is FDA-approved, and who prepares it should not disappear behind branding.
  11. Business · September 15, 2026GLP-1 Use Is Broadening. That Does Not Tell a Clinic Who Can Pay.A Gallup survey points to GLP-1 use reaching farther into the U.S. population. In its revised September report, Gallup estimated that 11 percent of adults currently took a GLP-1 medication for weight-loss purposes, compared with 3 percent in 2024. The 2026 survey was conducted from May 28 to June 5. Gallup revised its estimates on September 8 after updating the weighting criteria, so the revised figures, rather than an earlier snapshot, are the ones cited here.
  12. Policy · September 6, 2026A Proposed 503B Rule Draws a Different Line From the 503A DebateIn April, the FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. The agency said it did not identify a clinical need for outsourcing facilities to compound those drugs from bulk substances based on the nominations it reviewed. The agency sought public comments before a final determination.
  13. Policy · August 24, 2026The Pharmacy Landscape Is a Set of Rules, Not a Single NetworkA clinic can source across multiple channels and still find that the available choices are not interchangeable. State-licensed pharmacies operating under section 503A and FDA-registered outsourcing facilities under section 503B face different conditions. The FDA's April GLP-1 update makes that distinction explicit, while its 503A bulks page describes another layer: not every nominated ingredient is on a final approved bulks list.
  14. Peptides · August 9, 2026Peptides Move Onto the FDA Advisory CalendarA two-day FDA advisory committee meeting in July put several peptide-related bulk substances into a formal public discussion over the 503A bulks list. The agency's meeting page identifies substances under consideration, including BPC-157-related substances, KPV-related substances, TB-500, MOTS-C, semax and others. Background materials and a public docket were part of the process.
  15. Policy · July 26, 2026A Hormone-Therapy Label Change Has a Narrower Reach Than a HeadlineIn February, the FDA announced approved labeling changes for six menopausal hormone therapy products. It said the changes clarify risk considerations and followed a review of the scientific literature. More companies had submitted proposed changes at the agency's request, but the announced approvals concerned six products at the time of the release.
  16. Business · July 12, 2026A Supply Question Independent Clinics Cannot Solve With a CatalogTo a clinic buyer, supply can appear to be a simple question: is the item available? The FDA's compounding framework makes that answer incomplete. Under section 503A, eligibility to use a bulk drug substance depends on defined routes, including a qualifying monograph, an approved-drug component or a place on the 503A bulks list. The agency also describes documentation and manufacturer-registration requirements for bulk substances. Inclusion in an interim category is not the same as final placement on the statutory list.
  17. Policy · June 29, 2026FDA Warning Letters Turn the Spotlight Toward the Front PageThe pharmacy may be out of view, but the marketing is not. In March, the FDA announced warning letters to 30 telehealth companies over what it described as false or misleading claims about compounded GLP-1 products on their websites. The agency identified claims implying that a compounded product was the same as an FDA-approved drug. It also objected to branding that could make a platform appear to be the compounder without making the actual sourcing clear.
  18. Policy · June 14, 2026The End of the Shortage Is Not the End of the Compounding QuestionFor independent clinics, a drug's availability is only one part of the compounding question. The Food and Drug Administration's April update draws a sharper line around what happens when a commercially available drug is no longer in shortage: a compounded product does not become broadly interchangeable with an approved one simply because a practice can order it.
Free price check

Request your free price check.

Tell us about your practice. A person reads every request and replies by email, usually the same day.

All fields are required.

Do not include patient information. By submitting, you agree Clinic Wiz may contact you about this request.

What happens next

  1. A person at Clinic Wiz reads your request.
  2. We reply by email, usually the same day, with anything we need from you.
  3. We compare your pricing across our partners and show you the result.
  4. You get an offer that matches or beats your price. Switching is your call.

Prefer to talk? (786) 619-9661

Notes

Occasional notes from Clinic Wiz.

Short notes on pharmacy pricing and the business side of running a clinic. Unsubscribe anytime.